Surgical management of colorectal cancer liver metastases
C Padmanabhan, DP Nussbaum… - Surgical Oncology …, 2021 - surgonc.theclinics.com
Colorectal cancer is the second most common cancer diagnosis in women and the third
most common cancer diagnosis in men worldwide. 1 Approximately 1.8 million cases of …
most common cancer diagnosis in men worldwide. 1 Approximately 1.8 million cases of …
Oxaliplatin-based intra-arterial chemotherapy in colo-rectal cancer liver metastases: a review from pharmacology to clinical application
G Ranieri, M Laforgia, P Nardulli, S Ferraiuolo… - Cancers, 2019 - mdpi.com
Liver metastases (LM) are often consequences of colo-rectal cancer (CRC) and the majority
of patients have unresectable LM. Oxaliplatin-based intravenous chemotherapy represents …
of patients have unresectable LM. Oxaliplatin-based intravenous chemotherapy represents …
Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis
AJ Zacharias, TT Jayakrishnan, R Rajeev, WS Rilling… - PloS one, 2015 - journals.plos.org
Background Patients with unresectable Colorectal Liver Metastases (CRLM) are
increasingly being managed using Hepatic Artery Based Therapies (HAT), including Hepatic …
increasingly being managed using Hepatic Artery Based Therapies (HAT), including Hepatic …
Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: a randomized phase II study …
JS Kim, H Kim, SY Lee, YD Han, K Han, BS Min… - BMC cancer, 2023 - Springer
Background Although 80% of patients with metastatic colorectal cancer (CRC) experience
liver metastases, only 10–25% undergo resection at the time of diagnosis. Even in initially …
liver metastases, only 10–25% undergo resection at the time of diagnosis. Even in initially …
[HTML][HTML] Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases
A Boilève, A De Cuyper, A Larive, L Mahjoubi… - European Journal of …, 2020 - Elsevier
Background Hepatic arterial infusion (HAI) combined with systemic chemotherapy has
shown promising results in patients with unresectable colorectal liver metastases (CRLM) …
shown promising results in patients with unresectable colorectal liver metastases (CRLM) …
Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases
Background Hepatic arterial infusion chemotherapy (HAIC) has been shown to be beneficial
in the management of unresectable colorectal liver metastases (CRLM). This systematic …
in the management of unresectable colorectal liver metastases (CRLM). This systematic …
A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver …
AW Feng, JH Guo, S Gao, FX Kou, SX Liu, P Liu… - Frontiers in …, 2022 - frontiersin.org
Background The purpose was to compare the efficacy and safety of hepatic arterial infusion
(HAI) of oxaliplatin plus raltitrexed (TOMOX) to those of oxaliplatin plus 5-fluorouracil …
(HAI) of oxaliplatin plus raltitrexed (TOMOX) to those of oxaliplatin plus 5-fluorouracil …
5-fluorouracil treatment alters the efficiency of translational recoding
J Ge, J Karijolich, Y Zhai, J Zheng, YT Yu - Genes, 2017 - mdpi.com
5-fluorouracil (5-FU) is a chemotherapeutic agent that has been extensively studied since its
initial development in the 1950s. It has been suggested that the mechanism of action of 5-FU …
initial development in the 1950s. It has been suggested that the mechanism of action of 5-FU …
Outcomes of a phase I/II trial of hepatic arterial infusion of oxaliplatin combined with intravenous 5-fluorouracil and l-leucovorin in patients with unresectable liver …
Y Sato, Y Inaba, T Ura, H Nishiofuku… - Journal of …, 2018 - Springer
Purpose The purpose of this study was to assess hepatic arterial infusion (HAI) of oxaliplatin
combined with intravenous 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in colorectal cancer …
combined with intravenous 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in colorectal cancer …
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and …
E Fountzilas, E Krishnan, F Janku, S Fu… - Cancer chemotherapy …, 2018 - Springer
Background We investigated hepatic arterial infusion (HAI) oxaliplatin combined with
capecitabine+/− bevacizumab in advanced cancer with predominant liver involvement …
capecitabine+/− bevacizumab in advanced cancer with predominant liver involvement …